drugset / Trial / NCT03842943
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
NaSingle-groupOpen-labelOther
Summary
Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.
Timeline
- Start
- 2019-07-03
- Primary completion
- 2026-06-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Talimogene Laherparepvec | Other / unclassified | — | Other |